Form 4: Catalyst Pharma Chairman Gifts Shares to Family Trusts
Insider Transaction Report
Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, Inc., gifted 135,000 shares of common stock to irrevocable family trusts.
Summary
- Patrick J. McEnany, Chairman of the Board of Directors at Catalyst Pharmaceuticals, Inc. (CPRX), reported a series of transactions.
- On December 1, 2025, Mr. McEnany made three separate bona-fide gifts of 45,000 shares each of common stock, totaling 135,000 shares.
- These gifts were made to irrevocable trusts established for the benefit of his family members.
- The shares were transferred at a price of $0 per share, consistent with a gift.
- Following these transactions, Mr. McEnany's direct beneficial ownership of Catalyst Pharmaceuticals common stock stands at 4,148,477 shares.
- Mr. McEnany is not a trustee of these trusts and has no direct or indirect influence over their investment decisions.
Sentiment
Score: 5
Explanation: Neutral. A gift of shares by an insider for estate planning purposes is a routine event and does not typically reflect positively or negatively on the company's operational performance or future prospects. It is a personal financial decision.
Management Comments
- These transactions involved bona-fide gifts to irrevocable trusts for the benefit of family members of the Reporting Person.
- The beneficiaries do not share a household with the Reporting Person.
- The Reporting Person is not a trustee of any of the trusts, and the Reporting Person has no influence, whether direct or indirect, regarding investment decisions by the trusts.
Industry Context
This is an insider transaction report, which is company-specific and generally does not directly relate to broader industry trends unless it is part of a larger pattern of insider selling or gifting across the sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Structure | Transfer of 135,000 shares from direct beneficial ownership of the Chairman to irrevocable trusts for family members, with the Chairman explicitly stating no control over trust investment decisions. | 12/01/2025 | This change diversifies the beneficial ownership of shares while maintaining family interest, with no direct impact on corporate governance or voting control by the Chairman. |
Related Party Transactions
- Gifts of 135,000 shares of common stock to irrevocable trusts for the benefit of family members of the Reporting Person.
Stakeholder Impact
- Shareholders: Minimal direct impact on the company's operations or valuation. It represents a transfer of ownership rather than a sale into the open market.
- Management: Reflects personal financial planning by a key executive, with no stated impact on his role or commitment to the company.
Key Dates
| Date | Description |
|---|---|
| 12/01/2025 | Date of gifts of common stock to irrevocable trusts. |
| 12/03/2025 | Date of filing of the Statement of Changes in Beneficial Ownership (Form 4). |
Keywords
Catalyst Pharmaceuticals, CPRX, Patrick J. McEnany, Insider Transaction, Form 4, Stock Gift, Beneficial Ownership, Corporate Governance, Family Trust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.